BCM
CTKB icon

Bayesian Capital Management’s Cytek Biosciences CTKB Stock Holding History

Bayesian Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,900
Closed -$149K – 675
2024
Q4 		$149K Buy
+22,900
New +$136K 0.02% 593
2023
Q4 		– Sell
-14,950
Closed -$82.5K – 803
2023
Q3 		$82.5K Buy
+14,950
New +$120K 0.01% 621

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bayesian Capital Management's CTKB Position: Q1 2025 in Review

Bayesian Capital Management sold out of Cytek Biosciences (CTKB) in Q1 2025, closing a stake of 22,900 shares — an estimated $149K sold.

Bayesian Capital Management first reported a position in CTKB in Q3 2023 and held it in 2 quarters. The position peaked at $149K in Q4 2024. 160 funds tracked by Wall St. Rank hold CTKB as of Q1 2025.

  • Bayesian Capital Management reported no remaining Cytek Biosciences position as of Q1 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 22,900 Cytek Biosciences shares in Q1 2025, an estimated $149K.
  • Bayesian Capital Management first reported a position in Cytek Biosciences in Q3 2023 and held it in 2 quarters.
  • Bayesian Capital Management's Cytek Biosciences position peaked at $149K in Q4 2024.
  • 160 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2025.

Based on Bayesian Capital Management's 13F filing for Q1 2025, filed 15 May 2025.